Anbio Biotechnology · NASDAQ:NNNN
Anbio Biotechnology — IPO Roadshow (January 2025)
26 slides from Anbio Biotechnology's IPO roadshow presentation, Jan 22, 2025
Slide 1: Anbio: Improving Prognosis by Decentralizing Diagnostics
Anbio Improving Prognosis by Decentralizing Diagnostics Anbio
Slide 2: Forward-Looking Statements
Forward - Looking Statements Anbio Biotechnology Inc., or the Company, has filed a registration statement on Form F - 1 (File No. 333 - 284106) with the U.S. Securities and Exchange Commission, or the SEC, for the offering to which this free writing prospectus relates. Before you invest, you should
Slide 3: Preliminary Offering Summary
Preliminary Offering Summary *See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss. Anbio Biotechnology
Slide 4: Commitment to transforming the diagnostics landscape
Anbio Biotechnology’s unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of hea
Slide 5: Table of Contents
Table of Contents 1. Company Overview 2. Our Products 3. Industry Overview 4. Growth Strategies 5. Financials *See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investmen
Slide 6: Key Facts
Key Facts Company Founded in Incorporated in *See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss. Comp
Slide 7: Leadership Team
Leadership Team Significant leadership experience in the diagnostic space for developing and commercializing IVD instruments and consumables globally MICHAEL LAU, PhD, MBA - Chief Executive Officer • Ph.D. from University of California, Riverside • M.B.A. from University of Wisconsin • More than 10
Slide 8: Anbio is a Global Diagnostic Company
Anbio is a Global Diagnostic Company *See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative, illiquid and there is a risk of loss. Company Over
Slide 9: The Healthcare Landscape Is Evolving
THE HEALTHCARE LANDSCAPE IS EVOLVING Patient Healthcare Increasing importance of Chronic Disease Management Declining Population Health More focus on Precision Medicine High Demand for In - Vitro Diagnostics *See offering documents for further risks and disclosures. There are no guarantees that any
Slide 10: Improve Healthcare by Decentralization
Improve Healthcare by Decentralization Our portfolio of instruments and R&D Platform is intended to better patient’s quality of life by making diagnostics faster, more accessible, and more affordable globally Process can take up to 14 days or longer Back Data Goes to Picked by Patient goes to Health
Slide 11: Anbio Is Paving the Way for Decentralized Healthcare
ANBIO IS PAVING THE WAY OF THE FUTURE FOR DECENTRALIZED HEALTHCARE TRADITIONAL CARE DIAGNOSTICS ◗ Long time for test results ◗ Samples are sent to central laboratories ◗ Doctors are limited to tests that can be reimbursed by insurance OUR DIAGNOSTICS SOLUTION ◗ Rapid results within 20 minutes at the
Slide 12: Our Products
Our Products We are a Diagnostics Solutions Provider Anbio’s Fluorescent Immunochromatographic Solution (FIA) Portable reader with available assays suitable for laboratory, wellness, and point - of - care applications. Anbio’s Chemiluminescent Immunoassay Solution (CLIA) Automated and compact analyz
Slide 13: Comprehensive Portfolio of Diagnostic Assays
Anbio’s Comprehensive Portfolio of Diagnostic Assays Assays for Detection of Disease Biomarkers INFECTIOUS DISEASES ◗ Infectious diseases assays available for FIA, CLIA, MDx, and LFIA platforms CANCER ◗ Cancer assays available for FIA, CLIA, and LFIA platforms Molecular Diagnostics ◗ Molecular diagn
Slide 14: Our Product Development Philosophy
SPEED ◗ We focus on rapid test results for faster health solutions. AFFORDABLE INNOVATION ◗ We provide affordable diagnostic solutions and eliminate financial barriers often seen in our current system. ◗ We focus on diagnostic technology driven by mobility and ease of use. OUR PRODUCT DEVELOPMENT PH
Slide 15: Anbio's FIA Solution – Analyzer
ANBIO’S FIA SOLUTION – ANALYZER Easy to Use Portable Reader for Quantitative Biomarker Detection ANBIO BIOTECHNOLOGY AF - 100S Handheld Fluorescent Chromatographic Immunoassay (FIA) Solution The Anbio AF - 100S is a handheld, easy - to - use, affordable, and rapid point - of - care FIA that utilizes
Slide 16: Anbio's ADL i1910 CLIA Solution
ANBIO’S ADL i1910 CLIA SOLUTION Fully Automated Chemiluminescence Immunoassay Solution ANBIO BIOTECHNOLOGY ADL i1910 The Anbio ADL i1910 is a fully automated, compact, and affordable CLIA analyzer that adopts direct chemiluminescence method based on acridinium ester and works clinically with support
Slide 17: Anbio's LFIA Solution
ANBIO’S LFIA SOLUTION Anbio's LFIA utilizes the immunochromatography principle for visual detection of a specific biomarker in a sample. With available high - quality assays to visually detect analytes for various abnormalities including cardiovascular, cancer, infectious diseases, drug abuse, and h
Slide 18: Anbio's LAMP Solution
ANBIO’S LAMP SOLUTION Easy to Use, Portable MDx Testing Anbio's LAMP Solution, or Loop - Mediated Isothermal Amplification, is a diagnostic technique used to amplify and detect specific DNA or RNA sequences . The LAMP assay is used for various applications, including the detection of infectious dise
Slide 19: Pharmacogenomics Solution: RT-PCR Assay
Anbio simplifies the challenges faced in pharmacogenomics with our real - time PCR (RT - PCR) solutions approach that caters to the needs of both new and experienced users in quantitative reverse transcriptase PCR (qRT - PCR) and pharmacogenomics. Anbio’s portfolio of pharmacogenomics assays support
Slide 20: Winning the Global Diagnostic Market
WINNING THE GLOBAL DIAGNOSTIC MARKET Anbio is Well Positioned to Win in a Growing Global Diagnostic Market Immunoassays are emerging as a reliable field for aiding in the diagnosis and treatment guidance of cardiovascular diseases, infectious diseases, and cancer . The global immunoassay market exhi
Slide 21: Winning the Global Diagnostic Market (RT-PCR, LAMP)
WINNING THE GLOBAL DIAGNOSTIC MARKET Anbio is Well Positioned to Win in a Growing Global Diagnostic Market Global RT - PCR Market CAGR 6.8% *Source: BCC Research **Source : Isothermal Nucleic Acid Amplification Technology Market Size, Share & Trends Analysis Report By Product, By Technology (NASBA,
Slide 22: Anbio's Go-to-Market Strategy
ANBIO’S GO - TO - MARKET STRATEGY Strategic Approach to Expand Our IVD Market Share Market Expansion and Regulatory Approval •Focus on expanding global IVD market share through maturing and expanding sales, marketing, and distribution teams. •Target key regions: EU, APAC, North America, South Americ
Slide 23: Speed, Innovation and Low-Cost
Speed, Innovation and Low - Cost Given that global healthcare emphasis is shifting toward precision medicine, population health, and chronic disease management, Anbio develops and sell solutions to laboratory diagnostics and point - of - care technology in strategically selected markets. With a focu
Slide 24: Financial Highlights: Revenue
Financial Highlights Revenue FY2022 versus FY 2023 86% 14% FY2022 Revenue Breakdown by Region European Union Asia Pacific North America 69% 3% 1% 25% FY2023 Revenue Breakdown by Region 2% European Union South America Asia Pacific Other Regions North America $3,059,575.00 $5,849,633.00 2023 (6 months
Slide 25: Financial Highlights: Gross Profit and Net Income
Financial Highlights Gross Profit - FY2022 versus 2023 $1,797,021.00 $3,910,620.00 2023 (6 months) 2024 (6 months) Gross Profit - 2023 versus 2024 (6 months) $12,563,805.0 0 $3,360,869.00 FY2022 FY2023 $10,011,177.0 0 $2,253,709.00 FY2022 FY2023 Net Income - FY2022 versus FY2023 $1,520,626.00 *See o
Slide 26: Anbio Contact
Anbio Improving Prognosis by Decentralizing Diagnostics Anbio info@acsunshine.co m +1 689 - 689 - 9686 www.acsunshine.com *See offering documents for further risks and disclosures. There are no guarantees that any specific outcome will be achieved. Past performance is not indicative of future result